Related Experiment Videos
Immunotoxins and recombinant toxins in the treatment of solid carcinomas
1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Abstract:
Cancer remains the second most common cause of death in our society, and advanced disease is often refractory to surgical, chemotherapeutic, and radiologic interventions. One novel approach to cancer treatment involves targeting a cytotoxic agent to a cancer cell. Immunotoxins have been developed that contain a potent toxin (either Pseudomonas exotoxin, ricin toxin, or diphtheria toxin) coupled to a targeting moiety that directs the molecule to cells expressing a certain antigen. Chemically coupled immunotoxins have been developed over the past 12 years. These bind to and kill cells expressing many tumor-associated antigens. Initial clinical results were disappointing, but recent results have been more promising. Furthermore, newer immunotoxins have been developed that will soon be in clinical trials. Some of these are recombinant toxins that have been developed using techniques of genetic engineering. Transforming growth factor-alpha, acidic fibroblast growth factor, insulin-like growth factor-1, interleukin-2, interleukin-4, interleukin-6, the binding portions of monoclonal antibodies, and CD4 have been used to direct toxins to cancer cells or cells infected with the human immunodeficiency virus type 1. Efforts are under way to circumvent problems such as immunogenicity that may limit the clinical usefulness of immunotoxins.
Insights
Immunotoxins, which link potent toxins to cancer-targeting molecules, offer a novel approach to treating advanced cancers. While early trials were disappointing, newer genetically engineered immunotoxins show promise for improved clinical efficacy.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Cancer is a leading cause of death, with advanced stages often resistant to conventional treatments.
- Targeting cytotoxic agents directly to cancer cells presents a promising therapeutic strategy.
- Immunotoxins combine potent toxins with targeting moieties to selectively eliminate cancer cells.
Purpose of the Study:
- To review the development and clinical potential of immunotoxins for cancer therapy.
- To highlight advancements in immunotoxin design, including recombinant toxins and novel targeting moieties.
- To address challenges such as immunogenicity that may affect clinical utility.
Main Methods:
- Development of immunotoxins by chemically coupling toxins (e.g., Pseudomonas exotoxin, ricin, diphtheria toxin) to targeting ligands.
- Utilizing genetic engineering to create recombinant immunotoxins.
- Employing various targeting moieties such as growth factors, cytokines, antibodies, and CD4.
Main Results:
- Initial clinical trials with chemically coupled immunotoxins yielded disappointing results.
- Recent clinical outcomes with immunotoxins have shown more promise.
- Newer immunotoxin designs, including recombinant forms, are advancing towards clinical trials.
Conclusions:
- Immunotoxins represent a developing therapeutic modality for cancer treatment.
- Advancements in genetic engineering and targeting strategies are enhancing immunotoxin efficacy.
- Overcoming immunogenicity is crucial for maximizing the clinical benefit of immunotoxins.